行情

MCRB

MCRB

Seres
NASDAQ

实时行情|Nasdaq Last Sale

3.670
-0.010
-0.27%
盘后: 3.670 0 0.00% 16:40 12/06 EST
开盘
3.690
昨收
3.680
最高
3.730
最低
3.418
成交量
26.49万
成交额
--
52周最高
8.39
52周最低
2.020
市值
2.57亿
市盈率(TTM)
-2.3128
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MCRB 新闻

  • 意大利最大商业银行拟裁员8000人
  • 新浪财经.5天前
  • 意大利总理支持欧洲稳定机制改革 遭反对党批评
  • 中国新闻网.5天前
  • 韩2019网购销售额破100万亿韩元 披萨炸鸡交易额剧增
  • 中国新闻网.5天前
  • 意大利再次修正2020财政预算案 推多项惠民政策
  • 中国新闻网.5天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

MCRB 简况

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
展开

Webull提供Seres Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。